Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330863 · ClinicalTrials.gov registry record · Phase 4
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
A Phase 4 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 357
- Enrollment target
NCT00330863 is a Phase 4 study that has completed, run by Northwell Health. The registered enrollment target is 357 participants.
The verdict
NCT00330863, a Phase 4 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 357 participants
- Enrollment target
Study Summary
This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Quetiapine
- DRUG Ziprasidone
- DRUG Risperidone microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330863
The ClinicalTrials.gov registry entry for NCT00330863 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Risperidone is the first listed.
NCT00330863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330863 about?
NCT00330863 is a clinical study titled "Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy". This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
What is the current status of trial NCT00330863?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 357 participants. The study started on 2006-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00330863?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Quetiapine (DRUG), Ziprasidone (DRUG), Risperidone microspheres (DRUG).
Who is sponsoring clinical trial NCT00330863?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.